A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer (PERTAIN)
A Randomized, Two-Arm, Open-Label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab Plus an Aromatase Inhibitor in First Line Patients With HER2-Positive and Hormone Receptor-Positive Advanced (Metastatic or Locally Advanced) Breast Cancer
Sponsor: Hoffmann-La Roche
Listed as NCT01491737, this PHASE2 trial focuses on Breast Cancer and remains completed. Sponsored by Hoffmann-La Roche, it has been updated 19 times since 2012, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
19 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 14 earlier versions
-
Jan 2020 — Nov 2020 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Dec 2019 — Jan 2020 [monthly]
Active Not Recruiting PHASE2
-
Aug 2019 — Dec 2019 [monthly]
Active Not Recruiting PHASE2
-
May 2019 — Aug 2019 [monthly]
Active Not Recruiting PHASE2
-
Feb 2019 — May 2019 [monthly]
Active Not Recruiting PHASE2
-
Dec 2018 — Feb 2019 [monthly]
Active Not Recruiting PHASE2
-
Sep 2018 — Dec 2018 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Sep 2018 [monthly]
Active Not Recruiting PHASE2
-
Mar 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Dec 2017 — Mar 2018 [monthly]
Active Not Recruiting PHASE2
-
Jul 2017 — Dec 2017 [monthly]
Active Not Recruiting PHASE2
-
May 2017 — Jul 2017 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Feb 2017 — May 2017 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Feb 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hoffmann-La Roche
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain , Ankara, Turkey (Türkiye) , Atlanta, United States , Badalona, Spain , Bakersfield, United States , Baltimore, United States , Bangalore, India , Barcelona, Spain , Bari, Italy , Besançon, France and 63 more locations